Dosing considerations should be made in adults with advanced or end-stage renal impairment and those on hemodialysis. (2.4, 2.5) Treatment regimen: Adults and pediatric patients 13 years of age and older. The dosage should be 1 gram once a day intravenously or intramuscularly. (2.2) Patient...
No accumulation of ertapenem was seen at steady state following intravenous or intramuscular administration; the mean bioavailability of the drug following intramuscular administration is ≈90%. Ertapenem is highly plasma protein bound in a nonlinear concentration-dependent manner, and achieves good penetrati...
It has a relatively long plasma half-life that enables once-daily dosing, an advantage over imipenem and meropenem. Common adverse effects associated with the use of ertapenem include diarrhea, nausea, vomiting, headache, infusion-site complications, and altered mental status. Seizures have been ...
"Larger, prospective, randomizedclinical trialsare needed to further optimize ertapenem dosing and duration, to evaluate the coadministration of other therapies, and to develop strategies for maintaining therapeutic outcomes," the authors write. One author disclosed ties to Verrica Pharmaceuticals. DOI: ...
The modestly extended plasma half-life allows once-daily dosing. Excretion is predominantly by the renal route, about 80% being recovered in the urine within 24 h. About 40% is eliminated unchanged, the rest as a biologically inactive ringopened metabolite. Dosage should be reduced in severe ...
It has a relatively long plasma half-life that enables once-daily dosing, an advantage over imipenem and meropenem. Common adverse effects associated with the use of ertapenem include diarrhea, nausea, vomiting, headache, infusion-site complications, and altered mental status. Seizures have been ...
It is highly stable against nearly all beta-lactamases, including AmpC and extended spectrum beta lactamases.Ertapenem can be given intramuscularly or intravenously and its favourable pharmacokinetic profile allows once daily dosing. Ertapenemhas been proven to be clinically and bacteriologically ...
Background: Ertapenem is a new parenteral carbapenem effective as a single agent for treatment of community acquired and polymicrobial infections. Advantages include once daily dosing and cost effectiveness compared to other carbapenems. Commercial antimicrobial susceptibility tests do not yet routinely inclu...
Only 15% of patients received inappropriately high ertapenem dosing based on kidney function. Patients developed neurological signs and symptoms after a median of 4 days (interquartile range, 3鈥 9 days). The most common clinical features were seizures (70%), altered level of cons...
However, because most published carbapenems studies have excluded patients on dialysis, little is known about the dosing of ertapenem to avoid central nervous system (CNS) toxicity in regular HD patients. We report of four patients who developed CNS toxicity in such patients.Lee, K-HUeng, Y-...